Lakefront Biotherapeutics (LKFT) Consolidated Net Income (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 13 years of Consolidated Net Income data on file, last reported at $709471.9 in Q1 2026.

• Consolidated Net Income for Q1 2026 came in at $709471.9, down 41.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 million (down 90.01% YoY), and the FY2025 annual result was $1.6 million, down 97.99% from the prior year.
• Consolidated Net Income improved to $709471.9 in Q1 2026 per LKFT's latest filing, from -$399266.9 in the prior quarter.
• Over five years, Consolidated Net Income peaked at $212.8 million in Q4 2023 and troughed at -$64.6 million in Q4 2022.
• A 5-year average of $12.5 million and a median of $959569.5 in 2026 frame the typical range for Consolidated Net Income.
• The sharpest annual moves came in 2022 and 2023: Consolidated Net Income plunged 1116.56% in 2022, then jumped 429.51% in 2023.
• A 5-year view of Consolidated Net Income shows it stood at -$64.6 million in 2022, then jumped by 429.51% to $212.8 million in 2023, then tumbled by 96.89% to $6.6 million in 2024, then tumbled by 106.04% to -$399266.9 in 2025, then surged by 277.69% to $709471.9 in 2026.
• Business Quant data shows LKFT's Consolidated Net Income at $709471.9 in Q1 2026, -$399266.9 in Q4 2025, and $2.2 million in Q3 2025.